Ratings Hoya Corporation

Equities

7741

JP3837800006

Market Closed - Japan Exchange Other stock markets 02:34:43 2024-04-19 am EDT			5-day change	1st Jan Change
17,320 ^JPY	-2.31%		+1.94%	-1.73%

Apr. 05	Hoya Flags IT System Failure; Stock Falls 3%	MT
Apr. 04	Japanese lens maker Hoya halts production after cyberattack	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.17 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
HOYA CORPORATION	-1.73%	40.2B	B+
ABBOTT LABORATORIES	-2.53%	183B	C+
MEDTRONIC PLC	-3.52%	105B	C
DEXCOM, INC.	+5.33%	51.77B	B-
CENCORA, INC.	+16.43%	47.29B	B-
WEST PHARMACEUTICAL SERVICES, INC.	+5.66%	27.62B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	-2.01%	25.51B	B
TERUMO CORPORATION	+9.84%	24.73B	A-
ZIMMER BIOMET HOLDINGS, INC.	-1.87%	24.52B	B
ALIGN TECHNOLOGY, INC.	+9.12%	22.68B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes